Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Wow, a quick phase 2: only 10 subjects over 6 weeks - 3 weeks treatment, and 3 of follow-up. Primarily this is a safety study, looking at safety and PK of more frequent dosing. Also will look at samples (tumor biopsy, ascites, and blood) before and after treatment to see effects of kevetrin on various biomarkers (like p53, but also they were going to look at all kinds of RNA and other things) and I wouldn't expect to see much efficacy with only 3 weeks of treatment, but perhaps, just perhaps we could see some tumor shrinkage.

Was wondering how they were saying K could possibly be in a registration study in 2018. This Phase II should be very quick (for sure at least compared to the marathon of K Phase I).